Efficacy of the Glucosidase Inhibitor Acarbose Compared to the Sulfonylurea Glisoxepide on Metabolic Control in Diet-Treated Type II Diabetics

  • R. Mies
  • M. Spengler
  • U. Henke
  • K. Boehme
Conference paper

Abstract

α-Glucosidase inhibition is a new principle in the treatment of diabetes mellitus. To compare this new principle with the well-established sulfonylurea therapy of type II diabetes, we treated 20 type II diabetics with the α-glucosidase inhibitor acarbose or the sulfonylurea glisoxepide in a double-dummy, double-blind, crossover study with 4-week drug-free pretreatment, 2 treatment periods of 8 weeks, with 4 weeks of washout. Dosage per day was acarbose 3 × 50 mg in week 1, 3 × 100 mg in week 2, 3 × 200 mg in weeks 3–8, glisoxepide 2 × 4 mg. Nine male and 11 female patients treated solely by means of diet (6665 ± 1217 kJ/day) were included (age, 62 ± 9 years; Broca index, 1.05 ± 0.07; median duration of diabetes, 6 years).

Keywords

Washout Sulfonylurea Acarbose Glisoxepide 

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. Mies
    • 1
  • M. Spengler
    • 2
  • U. Henke
    • 1
  • K. Boehme
    • 2
  1. 1.Department of Internal MedicineSt. Antonius HospitalKöln 51Germany
  2. 2.Pharma Research CentreBayer AGWuppertal 1Germany

Personalised recommendations